Paroxysmal Nocturnal Hemoglobinuria (PNH)

Health-related quality of life and symptom-specific functional impairment among patients treated with parenterally administered complement inhibitors for paroxysmal nocturnal hemoglobinuria

This study describes the health-related quality of life (HRQoL) and symptom-specific functional impairment of patients with

ASH 2024 Update: Aplastic Anemia and PNH

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Presenter(s)
Taha Bat, MD
In this webinar, Dr. Taha Bat discusses research most relevant to patients reported over the past year on the biology and treatment on Aplastic Anemia and PNH. These studies were presented at the American Society of Hematology (ASH) 2024 meeting and their findings will be…

Bharadhwaj Kolipakkam, MD

Institution
VCU Health
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Subscribe to Paroxysmal Nocturnal Hemoglobinuria (PNH)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.